Firmonertinib holds a second-line NSCLC approval; the thesis turns on whether the FURVENT Phase 3 readout unlocks first-line exon 20 insertion labeling

Bull

A positive ALPACCA readout demonstrating statistically significant progression-free survival improvement versus osimertinib or afatinib in first-line EGFR PACC mutant NSCLC would validate firmonertinib as a differentiated first-line EGFR TKI beyond exon 20 insertions, expanding the addressable patient population and supporting a broader EGFR franchise narrative. Combined with the existing second-line approval, this would position firmonertinib as a multi-indication EGFR platform asset and substantially increase peak revenue estimates, likely driving a meaningful re-rating of the stock.

Bear

The most likely failure mode is insufficient differentiation versus osimertinib, which already has deep first-line EGFR data and broad physician adoption — if firmonertinib does not demonstrate a clear PFS or overall survival advantage, the trial could be considered a de facto negative even with nominal efficacy. Additional risks include slower-than-expected enrollment in a molecularly rare PACC mutation subpopulation, imbalanced randomization in a small population undermining statistical power, or a safety signal at the 240 mg dose that complicates the benefit-risk profile versus established alternatives.